Compare Roundhill Magnificent Seven ETF (MAGS) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill Magnificent Seven ETF vs Summit Therapeutics Inc — how do they compare? Roundhill Magnificent Seven ETF trades at $67.68, while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: Roundhill Magnificent Seven ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| MAGS | SMMT | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $70.94 | $26.98 |
52-Week Low | $55.39 | $12.55 |
Market Cap | — | $12.06B |
Enterprise Value | — | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MAGS (Roundhill Magnificent Seven ETF) trades at $67.71, down 1.93% amid broader rotation away from concentrated tech exposure. Technical indicators show bullish moving averages but overbought RSI levels, with key support at $67. Recent news highlights the ETF's 181% gain since launch but notes underperformance versus the S&P 500 this year as AI spending pressures tech balance sheets.
The ETF faces headwinds from compressed hyperscaler valuations and declining payout ratios, though AI revenue growth potential remains. Risks include concentration in seven mega-caps and market broadening away from tech leadership. Analyst sentiment is mixed, balancing long-term AI themes against near-term valuation concerns.
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
